Date:_2021-11-13	
Your Name: <u>Kang Ning</u>	
Manuscript Title: Immune Checkp	oint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell
Carcinoma after Long-term Target	ed Therapy
Manuscript number (if known):	TAIL-21-1015

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

,			
	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
	Payment for expert	_ XNone	
	testimony		
	Support for attending	X None	
	meetings and/or travel		
	g .		
_			
	Patents planned, issued or	XNone	
	pending		
ightharpoons			
	Participation on a Data	_ XNone	
	Safety Monitoring Board or		
	Advisory Board		
1	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
	Stock or stock options	_ XNone	
	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
	Other financial or non-	X None	
	financial interests		
	mandar meereses		
_			
	ase summarize the above c	onflict of interest in the	e following box:
le			
	None.		

form.

Date:_2022-1-27
Your Name:_Zeshen Wu
Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cel
Carcinoma after Long-term Targeted Therapy
Manuscript number (if known): TAU-21-1015

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

,			
	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
	Payment for expert	_ XNone	
	testimony		
	Support for attending	X None	
	meetings and/or travel		
	g .		
_			
	Patents planned, issued or	XNone	
	pending		
ightharpoons			
	Participation on a Data	_ XNone	
	Safety Monitoring Board or		
	Advisory Board		
1	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
	Stock or stock options	_ XNone	
	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
	Other financial or non-	X None	
	financial interests		
	mandar meereses		
_			
	ase summarize the above c	onflict of interest in the	e following box:
le			
	None.		

form.

Date: 2021-11-13

Your Name: Xiangpeng Zou

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

Carcinoma after Long-term Targeted Therapy

Manuscript number (if known): __TAU-21-1015_______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: pastXNoneXNone	36 months
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	_ XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ XNone	
	testimony		
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	_XNone	
	pending		
_			
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	ease summarize the above c	onflict of interest in the	following box:

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13 Your Name: Huiming Liu

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	_ XNone	
	testimony		
_		V 1	
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	_ XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V N	
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	_ ^NUITE	
	writing, gifts or other		
	services		
13	Other financial or non-	_ XNone	
	financial interests		

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>2021-11-13</u> Your Name: <u>Yi Wu</u>

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u> Manuscript number (if known):____ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time illuit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13

Your Name: Longbing Xiong

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u>
Manuscript number (if known):__ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13

Your Name: Chunping Yu

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u> Manuscript number (if known):_ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13

Your Name: Shengjie Guo

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u>
Manuscript number (if known):___ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_ XNone	
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	30 months
_	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13 Your Name: Hui Han

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u> Manuscript number (if known):____ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone	
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13

Your Name: Fangjian Zhou

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u>
Manuscript number (if known):___ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13 Your Name: Pei Dong

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u>
Manuscript number (if known):__ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-11-13

Your Name: Zhiling Zhang

Manuscript Title: Immune Checkpoint Inhibitors Further Aggravate Proteinuria in Patients With Metastatic Renal Cell

<u>Carcinoma after Long-term Targeted Therapy</u> Manuscript number (if known):_ TAU-21-1015_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ XNone
6	Payment for expert testimony	_ XNone
7	Support for attending meetings and/or travel	_ XNone
8	Patents planned, issued or pending	_ XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ XNone
11	Stock or stock options	_ XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ XNone
13	Other financial or non- financial interests	_ XNone

None.			

Please place an "X" next to the following statement to indicate your agreement: